It is therefore possible that clusterin could be used in conjunction with cognitive testing with tests such as the ECAS, to improve the sensitivity of the detection of TDP‐43 pathology in nonmotor brain regions, in ALS patients and improve (i) prognostication regarding risk of developing cognitive impairment and (ii) stratification for clinical trials. This evidence concerns the gene CLU and amyotrophic lateral sclerosis.